
StudyFinder
Development of a RET-Specific Proteomic Assay from Circulating Tumor Cells in Lethal Prostate Cancer

Status: Recruiting
The goal of this study is to find a special protein in the blood of individuals with serious prostate cancer. Special tests look for this protein in their blood while they are getting their regular cancer treatments.
Sex: Male
Age Group: 18 years and over
Inclusion Criteria:
• diagnosis of metastatic castration resistant prostate cancer receiving a standard-of-care systemic therapy (e.g. abiraterone acetate, enzalutamide, darolutamide, or chemotherapy).
Exclusion Criteria:
• known HIV positivity and/or active Hepatitis B based on medical history
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), MCRPC, metastatic castration resistant prostate cancer
Study Contact: Skylar Mast - smast@umn.edu
Principal Investigator: Emmanuel Antonarakis
IRB Number: STUDY00023289